Anti-IgE therapy.
Controlling the IgE response at either the synthesis level or the effector phase should have a profound impact on the allergic cascade. For more than a decade, researchers have focused on ways of interfering with the binding of IgE to its high-affinity receptor on proinflammatory cells. Several approaches have also been taken to antagonize the complex interplay of cytokines and cell-associated molecules (CD40, CD23) that are implicated in IgE synthesis. Recently, anti-IgE antibodies have been developed that are potent IgE antagonists. These antibodies are currently under clinical investigation as potential therapeutics for allergic disease.
Jardieu
P
P
Department of Immunology, Genentech Inc, San Francisco, CA 94080, USA.
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis / Q000276:immunology / Q000627:therapeutic use*; D001323:Autoantibodies / Q000096:biosynthesis; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000628:therapy*; D007073:Immunoglobulin E / Q000096:biosynthesis / Q000276:immunology* / Q000378:metabolism; D008222:Lymphokines / Q000276:immunology; D051379:Mice; D017455:Receptors, IgE / Q000037:antagonists & inhibitors / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D001323:Autoantibodies; D008222:Lymphokines; D017455:Receptors, IgE; D007073:Immunoglobulin E